Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,699 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study.
Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R. Townsend W, et al. Among authors: marcus r. Hemasphere. 2023 Jun 30;7(7):e919. doi: 10.1097/HS9.0000000000000919. eCollection 2023 Jul. Hemasphere. 2023. PMID: 37404773 Free PMC article.
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.
Herold M, Hoster E, Janssens A, McCarthy H, Tedeschi A, Pocock C, Rosta A, Trněný M, Nielsen TG, Knapp A, Hiddemann W, Marcus R. Herold M, et al. Among authors: marcus r. Hemasphere. 2022 Feb 24;6(3):e699. doi: 10.1097/HS9.0000000000000699. eCollection 2022 Mar. Hemasphere. 2022. PMID: 35233508 Free PMC article.
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Marcus R, et al. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598. N Engl J Med. 2017. PMID: 28976863 Free article. Clinical Trial.
Obinutuzumab Treatment of Follicular Lymphoma.
Marcus R, Seymour JF, Hiddemann W. Marcus R, et al. N Engl J Med. 2017 Dec 28;377(26):2605-2606. doi: 10.1056/NEJMc1714337#SA2. N Engl J Med. 2017. PMID: 29281572 No abstract available.
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Hiddemann W, et al. Among authors: marcus re. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1. J Clin Oncol. 2018. PMID: 29856692 Clinical Trial.
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W. Seymour JF, et al. Among authors: marcus r. Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20. Haematologica. 2019. PMID: 30573503 Free PMC article.
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Jamois C, Gibiansky E, Gibiansky L, Buchheit V, Sahin D, Cartron G, Marcus R, Hiddemann W, Seymour JF, Strefford JC, Hargreaves CE, Meneses-Lorente G, Frey N, Fingerle-Rowson G. Jamois C, et al. Among authors: marcus r. Br J Clin Pharmacol. 2019 Jul;85(7):1495-1506. doi: 10.1111/bcp.13920. Epub 2019 May 17. Br J Clin Pharmacol. 2019. PMID: 30866056 Free PMC article. Clinical Trial.
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.
Rutherford SC, Herold M, Hiddemann W, Kostakoglu L, Marcus R, Martelli M, Sehn LH, Trněný M, Trotman J, Vitolo U, Nielsen T, Mattiello F, Sahin D, Sellam G, Martin P. Rutherford SC, et al. Among authors: marcus r. Blood Adv. 2020 Apr 28;4(8):1589-1593. doi: 10.1182/bloodadvances.2019001261. Blood Adv. 2020. PMID: 32298429 Free PMC article.
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
Mir F, Mattiello F, Grigg A, Herold M, Hiddemann W, Marcus R, Seymour JF, Bolen CR, Knapp A, Nielsen T, Casulo C. Mir F, et al. Among authors: marcus r. Am J Hematol. 2020 Dec;95(12):1503-1510. doi: 10.1002/ajh.25973. Epub 2020 Sep 16. Am J Hematol. 2020. PMID: 32815559 Free PMC article. Clinical Trial.
1,699 results